Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
28 Setembro 2023 - 4:00AM
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced the presentation of interim data for the 2.15 to 12 mg
target dose cohorts from its Phase 1 clinical trial evaluating
single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM).
HPN217 targets B-cell maturation antigen (BCMA) and is based on
Harpoon’s proprietary Tri-specific T cell Activating Construct
(TriTAC®) platform designed to recruit a patient’s immune cells to
kill tumor cells. The data will be presented at the 20th
International Myeloma Society (IMS) Annual Meeting in a poster
presentation on September 28, 2023 in Athens, Greece.
As of the data cut-off on August 12, 2023, 97 patients were
treated with HPN217 across 14 dose escalation cohorts. The trial
enrolled heavily pre-treated patients, of whom 65% were penta-drug
exposed and 20% had been treated with BCMA-targeted agents.
In patients at the 12 mg target dose (N=19), a manageable
tolerability profile was observed with low rates of CRS (16%, all
G1-2) and no ICANS. Additionally, robust, early clinical activity
(63% ORR) was seen. Treatment remains ongoing in 7 responders,
while the median responder time on treatment continues to mature,
currently 8.3 months (6.0-17.3+).
For the earlier 2.15 mg to 6 mg target dose cohorts, the median
responder time on treatment was 21.8 months (10.4-27.5+), with
several remaining on treatment with a sustained response.
“The early and durable responses at the 12 mg cohort of HPN217
in an RRMM patient population that has undergone extensive prior
treatments are encouraging. The 63% overall response rate at the
target dose level is strong, with many responses occurring early
and deepening over time,” said Luke Walker, M.D., Chief Medical
Officer for Harpoon Therapeutics. “The low frequency of CRS and
compelling efficacy continue to support late-stage development of
HPN217 and its potential to become a differentiated option for
patients.”
Enrollment in dose escalation cohorts up to 24 mg is complete,
and the maximum tolerated dose (MTD) has not been reached. Follow
up is ongoing, and the evaluation of regimens will inform the
choice of a recommended Phase 2 dose(s) at year end 2023.
The poster will be available on Harpoon’s website following the
presentation.
For more details about the IMS Annual Meeting, please visit:
https://events.jspargo.com/ims23/Public/Content.aspx?ID=102336&sortMenu=101000
About Harpoon Therapeutics Harpoon Therapeutics
is a clinical-stage immuno-oncology company developing a novel
class of T cell engagers that harness the power of the body’s
immune system to treat patients suffering from cancer and other
diseases. T cell engagers are engineered proteins that direct a
patient’s own T cells to kill target cells that express specific
proteins, or antigens, carried by the target cells. Using its
proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel TriTACs
initially focused on the treatment of solid tumors and hematologic
malignancies. Harpoon has also developed a proprietary ProTriTAC™
platform, which applies a prodrug concept to its TriTAC platform to
create a therapeutic T cell engager that remains inactive until it
reaches the tumor. Harpoon’s third proprietary technology platform,
extended release TriTAC-XR, is designed to mitigate cytokine
release syndrome. For additional information about Harpoon
Therapeutics, please visit www.harpoontx.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “continue,” “further,” “remain,”
“will,” and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
These forward-looking statements involve risks and uncertainties
that could cause Harpoon Therapeutics’ clinical development
programs, future results, or performance to differ significantly
from those expressed or implied by the forward-looking statements.
Forward-looking statements in this press release include but are
not limited to, statements about the expected progress, results,
and plans pertaining to Harpoon Therapeutics’ clinical trials,
including timing, scope, design, enrollment plans and interim
results of clinical trials and the safety and tolerability profile
of product candidates, the association of interim clinical data and
preclinical results with potential treatment outcomes, achievement
of future milestones and other statements that are not historical
fact. These and other factors that may cause Harpoon Therapeutics’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Harpoon Therapeutics’ filings with the U.S. Securities and
Exchange Commission, including under “Risk Factors” in Harpoon
Therapeutics’ quarterly report on Form 10-Q for the quarter
ended June 30, 2023, and future filings by Harpoon
Therapeutics. Except as required by law, Harpoon
Therapeutics assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
ContactInvestors and media:Ana KaporHarpoon
Therapeutics akapor@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Harpoon Therapeutics (NASDAQ:HARP)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024